Historically, China has gone to great lengths to keep drug development within its borders—the government invests heavily in the industry, and has made it cost-prohibitive for foreign drug makers to enter the market. But recently, the scandals surrounding Changchun Changsheng Biotechnology, China’s second-largest maker of rabies vaccines, and Zhejiang Huahai Pharmaceutical, the maker of the now-recalled blood pressure drug Valsartan, have Chinese nationals looking outward, and have even sparked regulatory reforms. This lost faith in local drug companies begs the question: what does this mean for foreign investors?

The backlash from the public—heightened by the response of Chinese President Xi Jinping, who called the situation appalling—has put pressure on the Chinese government to create additional reforms to the ‘Opinions on Reforming the Review and Approval System for Drugs and Medical Devices’, and attract foreign investment. The government, in conjunction with the National Medical Products Administration (formerly known as the China Food and Drug Administration, or CFDA), has already taken a number of positive steps in recent years, including the acceptance of overseas clinical trial data of medical devices (January 2018). These recent scandals from July have further pushed the NMPA to accept overseas clinical trial data for drugs.

According to Vikas Bedi, APAC Healthcare Research Director at GlobalData, “The market is surely and steadily opening up to global players by shunning protectionism and projecting an image of efficiency, transparency, and opportunity.” It will be important for pharmaceutical and biopharmaceutical players to track additional Chinese reforms and capitalize on China’s aging population, resulting in the increasing demand for drugs.

TransPerfect Life Sciences is strengthening its position in China to meet growing needs through its recent acquisition of TranslateNow. An expert in Asian language services, TranslateNow adds local operations in Shenzhen to TransPerfect’s global footprint, which already includes offices in Beijing and Hong Kong. TransPerfect is the world’s largest provider of language services and technology solutions to life sciences organizations, and is strategically positioning itself to capture the growing opportunity in the Asian marketplace.